Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126886833 | 12688683 | 3 | F | 20160906 | 20160825 | 20160912 | EXP | BR-ABBVIE-16P-020-1710383-00 | ABBVIE | 19.00 | YR | F | Y | 0.00000 | 20160912 | MD | COUNTRY NOT SPECIFIED | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126886833 | 12688683 | 1 | PS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | UNKNOWN | 21226 | SOFT CAPSULE | QD | ||||||||
| 126886833 | 12688683 | 2 | SS | LAMIVUDINE W/TENOFOVIR DISOPROXIL | LAMIVUDINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | UNKNOWN | 0 | BID | |||||||||
| 126886833 | 12688683 | 3 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Intravenous (not otherwise specified) | 2 MG/KR/HR 1ST COURSE | UNKNOWN | 0 | |||||||||
| 126886833 | 12688683 | 4 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Intravenous (not otherwise specified) | 1 MG/KR/HR 2ND COURSE | UNKNOWN | 0 | |||||||||
| 126886833 | 12688683 | 5 | C | FOLATE | FOLATE SODIUM | 1 | 0 | ||||||||||||
| 126886833 | 12688683 | 6 | C | METRONIDAZOLE. | METRONIDAZOLE | 1 | 0 | ||||||||||||
| 126886833 | 12688683 | 7 | C | SULFAMETHOXAZOLE AND TRIMETHOPRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | 0 | ||||||||||||
| 126886833 | 12688683 | 8 | C | AZITHROMYCIN ANHYDROUS. | AZITHROMYCIN ANHYDROUS | 1 | 0 | ||||||||||||
| 126886833 | 12688683 | 9 | C | CEFTRIAXONE. | CEFTRIAXONE | 1 | 0 | ||||||||||||
| 126886833 | 12688683 | 10 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126886833 | 12688683 | 1 | HIV infection |
| 126886833 | 12688683 | 2 | HIV infection |
| 126886833 | 12688683 | 3 | HIV infection |
| 126886833 | 12688683 | 5 | Vitamin supplementation |
| 126886833 | 12688683 | 6 | Product used for unknown indication |
| 126886833 | 12688683 | 7 | Product used for unknown indication |
| 126886833 | 12688683 | 8 | Product used for unknown indication |
| 126886833 | 12688683 | 9 | Product used for unknown indication |
| 126886833 | 12688683 | 10 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126886833 | 12688683 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126886833 | 12688683 | Exposure during pregnancy | |
| 126886833 | 12688683 | Flavivirus infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126886833 | 12688683 | 1 | 20150505 | 0 | ||
| 126886833 | 12688683 | 2 | 20150505 | 0 | ||
| 126886833 | 12688683 | 3 | 20160816 | 20160816 | 0 | |
| 126886833 | 12688683 | 4 | 20160816 | 20160816 | 0 |